This activity is part 1 of a 3-part webinar curriculum and includes a Powered by Patients™ video interview.
Program Description
Chronic obstructive pulmonary disease (COPD) has distinct inflammatory phenotypes, including eosinophilia, which have been found to drive acute exacerbations in certain patients. Insights into the underlying mechanisms of the disease, including the involvement of type 2 inflammation and interleukins, and potential therapeutic targets will be shared. Patients may experience a significant burden imposed by untreated or undertreated COPD, as well as comorbidities that contribute to a higher risk of morbidity and mortality. This first webinar in the COPD curriculum will examine the pathophysiology of COPD and the impact of COPD exacerbations on patient health and well-being.
Target audience: Health-system, retail, and specialty pharmacists
Type of activity: Application
Release date: July 23, 2024
Expiration date: September 23, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the impact of chronic obstructive pulmonary disease (COPD) on patients' quality of life, including financial burden, hospitalizations, and morbidity
- Explain the involvement of type 2 inflammation and interleukins in the pathophysiology of COPD and eosinophilic phenotypes
- Identify risk factors that elevate a patient’s risk for COPD exacerbations
